MedTrace Logo

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-01-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

Conditions

Interventions

DRUG

Psilocybin

One individual oral psilocybin treatment session

BEHAVIORAL

Modified brief Supportive Expressive Group Therapy

Ten sessions of twice-weekly manualized group therapy

Sponsors & Collaborators

  • Heffter Research Institute

    collaborator OTHER

  • RiverStyx Foundation

    collaborator OTHER

  • Usona Institute

    collaborator OTHER

  • Stupski Foundation

    collaborator OTHER

  • Joshua Woolley

    lead OTHER

Principal Investigators

  • Joshua Woolley, MD,PhD · University of California, San Francisco

  • Brian Anderson, MD,MSc · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-05
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02950467 on ClinicalTrials.gov